查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1946399

思覺失調症藥物類別、給藥途徑、地區及競爭格局分類，2021-2031年）

Schizophrenia Drugs Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Drug Class, By Route Of Administration, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球思覺失調症治療市場預計將從 2025 年的 64.5 億美元成長到 2031 年的 84.8 億美元，複合年成長率為 4.67%。

該市場涵蓋一系列抗精神病藥物和輔助性治療，旨在控制這些慢性精神障礙的陽性症狀、陰性症狀和認知症狀。推動這一成長的關鍵因素包括：全球精神障礙盛行率的上升、長效注射劑（LAI）製劑的日益普及（提高了患者依從性），以及醫療基礎設施的不斷完善，從而提高了診斷和治療率。國際藥品製造商協會聯合會（IFPMA）的報告顯示，到2025年，全球將有約10億人受到某種形式的精神疾病的影響，這將顯著增加對有效治療性介入和先進藥物解決方案的需求。

市場概覽
預測期 2027-2031
市場規模：2025年 64.5億美元
市場規模：2031年 84.8億美元
複合年成長率：2026-2031年 4.67%
成長最快的細分市場 口服
最大的市場 北美洲

然而，該市場面臨許多挑戰，包括用藥依從性低以及許多現有療法存在嚴重的副作用。患者常因METABOLIC INC.症候群和體重增加等副作用而停止治療，這可能導致疾病復發，並因住院治療而增加經濟負擔。其他挑戰還包括新藥研發成本高昂、監管核准流程嚴格以及學名藥藥對過期品牌藥的競爭造成的商業性侵蝕。因此，製造商必須克服這些複雜的臨床和經濟挑戰，才能在全球競爭激烈的市場環境中維持長期成長。

市場促進因素

針對全新作用機制的新型治療方法的問世，標誌著市場格局的根本性轉變，其治療範圍超越了傳統的多巴胺受體拮抗劑，涵蓋了更廣泛的疾病。毒蕈鹼促效劑的出現凸顯了這種轉變，這類藥物在提供療效的同時，也能減少傳統抗精神病藥物通用的代謝副作用。製造商正積極開發這些藥物，以惠及更廣泛的患者群體。正如勃林格殷格翰在2024年5月的新聞稿中所指出的，思覺失調症影響著全球約2,400萬人，這為這些創新化合物創造了龐大的目標族群。這些突破性治療方法的商業性潛力正在推動大量投資，而百時美施貴寶在2024年3月以140億美元收購Karuna Therapeutics的交易，更凸顯了這些新一代治療方法的高市場價值。

同時，長效注射劑的日益普及正在重塑市場競爭格局，為解決藥物依從性低這一普遍難題提供了一個切實可行的方案。這些給藥系統將每日口服片劑的給藥頻率降低至每月或每半年注射一次，顯著改善了患者的治療效果，並降低了與復發相關的住院率。醫療機構優先選擇這些製劑，以確保穩定的生物利用度並簡化疾病管理通訊協定，從而為主要市場參與者創造了穩定的收入來源。例如，強生公司在2024年10月報告稱，其Invega Sustena和Invega Hafiela產品線的全球銷售額在第三季度達到10.5億美元，表明該公司將繼續依賴長效治療方案來實現持續成長。

市場挑戰

目前抗精神病藥物治療的持續不遵從性和嚴重的副作用，對全球思覺失調症治療市場的擴張構成了重大障礙。患者常遭受嚴重的副作用，包括代謝症候群和顯著的體重增加，嚴重降低其生活品質和身體健康。這些耐受性問題往往導致治療中斷，阻礙後續治療，並加劇復發率。因此，該市場以間歇性用藥模式而非穩定的長期用藥為特徵，這使得製造商無法充分挖掘已確診患者群體的商業性潛力，並限制了永續的收入成長。

這種身體健康負擔的直接影響是可量化的且十分嚴重的，降低了目標市場的整體永續性和穩定性。根據世界衛生組織（世衛組織）2025年的數據，思覺失調症患者的平均壽命比一般人群短約9年，這種差異主要由合併的軀體疾病（例如心血管疾病和代謝性疾病）造成。這種高死亡率，加上藥物的代謝副作用，抑制了患者群體的擴大，並為市場滲透創造了嚴峻的挑戰。

市場趨勢

將數位療法應用於藥物依從性監測和症狀管理是全球思覺失調症治療市場的變革性趨勢，它提供了一種非藥物治療方案，可以滿足諸如陰性症狀等未被滿足的需求。與傳統藥物療法不同，這些基於軟體的介入措施將患者與實證治療技術直接連接起來，即時追蹤患者的依從性，同時著重改善其認知和動機。隨著製造商尋求利用能夠改變疾病進展的數位工具來提高藥物療效，這種方法正獲得顯著的關注。勃林格殷格翰於2025年10月報告稱，其在研處方數位療法CT-155已證實，將數位技術與標準抗精神病藥物療法相結合具有臨床療效，在CAINS-MAP量表上，陰性症狀嚴重程度顯著改善了6.8分。

同時，經皮給藥系統的擴展正在豐富治療選擇，使其不再局限於口服片劑和長效注射劑，尤其是在提高生物利用度和減少副作用方面。經皮吸收貼片能夠持續、可控地釋放抗精神病藥物，從而減輕口服給藥時常見的血漿峰谷濃度波動，而這種波動往往是導致副作用的原因。這種給藥方式能夠讓看護者直覺地確認患者的用藥依從性，並且無需注射這種侵入性手段，即可解決思覺失調症治療中的一大難題。根據Alto Neuroscience公司截至2025年3月的會計年度財務報告，該公司的新型經皮製劑ALTO-101展現出比口服製劑更高的全身藥物暴露量，同時顯著降低了該類藥物常見的不利事件，這表明貼劑技術有望提高治療指數。

目錄

第1章概述

第2章調查方法

第3章執行摘要

第4章：客戶評價

第5章 全球思覺失調症藥物市場展望

  • 市場規模及預測
    • 按金額
  • 市佔率及預測
    • 依藥物類別（第一代、第二代、第三代藥物）
    • 給藥途徑（注射、口服）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美思覺失調症藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

7. 歐洲思覺失調症藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

8. 亞太地區思覺失調症藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

9. 中東和非洲思覺失調症藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲思覺失調症藥物市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章 市場動態

  • 促進要素
  • 任務

第12章 市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章 全球思覺失調症藥物市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的可能性
  • 供應商電力
  • 顧客權力
  • 替代品的威脅

第15章 競爭格局

  • Alkermes Plc
  • Eli Lilly and Company.
  • Johnson & Johnson.
  • AstraZeneca.
  • Pfizer Inc.
  • AbbVie Inc.
  • Otsuka Pharmaceutical Inc.
  • Bristol-Myers Squibb Company.
  • Sumitomo Dainippon Pharma.
  • Acadia Pharmaceuticals.

第16章 策略建議

第17章：關於研究公司及免責聲明

簡介目錄
Product Code: 19876

The Global Schizophrenia Drugs Market is projected to expand from USD 6.45 Billion in 2025 to USD 8.48 Billion by 2031, registering a compound annual growth rate of 4.67%. This market encompasses a variety of antipsychotic medications and adjunctive therapies aimed at managing the positive, negative, and cognitive symptoms of this chronic psychiatric disorder. Key drivers of this growth include the rising global prevalence of mental health conditions, the increasing uptake of long-acting injectable (LAI) formulations that enhance patient adherence, and the development of healthcare infrastructure that supports improved diagnosis and treatment rates. As reported by the International Federation of Pharmaceutical Manufacturers & Associations, approximately one billion people globally were affected by a mental health condition in 2025, creating a substantial and rising demand for effective therapeutic interventions and advanced pharmacological solutions.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 6.45 Billion
Market Size 2031USD 8.48 Billion
CAGR 2026-20314.67%
Fastest Growing SegmentOral
Largest MarketNorth America

However, the market confronts significant barriers related to medication non-adherence and the harsh side effect profiles associated with many existing treatments. Patients frequently discontinue therapy due to adverse reactions such as metabolic syndrome and weight gain, which often leads to disease relapse and increases the economic burden of hospitalization. Additionally, the high costs of developing novel drugs, rigorous regulatory approval pathways, and the commercial erosion caused by generic competition for patent-expired brands present considerable challenges. Consequently, manufacturers must navigate these complex clinical and economic hurdles to maintain long-term growth within the competitive global landscape.

Market Driver

The introduction of novel therapies targeting new mechanisms of action marks a fundamental shift in the market, moving beyond traditional dopamine receptor antagonism to address a wider range of symptoms. This transition is highlighted by the emergence of muscarinic agonists, which offer efficacy while reducing the metabolic side effects common in older antipsychotics. Manufacturers are aggressively pursuing these assets to secure a larger share of the patient population. As noted by Boehringer Ingelheim in a May 2024 press release, schizophrenia affects approximately 24 million people worldwide, presenting a vast target demographic for these innovative compounds. The commercial potential of such breakthroughs has triggered substantial investment, evidenced by Bristol Myers Squibb's acquisition of Karuna Therapeutics for a total equity value of $14.0 billion in March 2024, underscoring the high market valuation of next-generation treatments.

Concurrently, the increasing adoption of long-acting injectable formulations is reshaping the competitive landscape by offering a practical solution to the pervasive issue of medication non-adherence. By reducing dosing frequency from daily oral tablets to monthly or biannual injections, these delivery systems significantly improve patient outcomes and decrease relapse-associated hospitalization rates. Healthcare providers are prioritizing these formulations to ensure consistent bioavailability and streamline disease management protocols, resulting in robust revenue streams for key market players. For instance, Johnson & Johnson reported in October 2024 that global sales for their Invega Sustenna and Invega Hafyera franchise reached $1.05 billion for the third quarter, demonstrating the sustained and growing reliance on long-acting therapeutic options.

Market Challenge

The persistence of medication non-adherence and severe side effect profiles in current antipsychotic treatments constitutes a critical impediment to the expansion of the Global Schizophrenia Drugs Market. Patients often suffer from debilitating adverse reactions, including metabolic syndrome and significant weight gain, which drastically diminish their quality of life and physical well-being. These tolerability issues frequently drive individuals to discontinue therapy, disrupting the continuity of care and leading to high rates of disease relapse. Consequently, the market is characterized by fragmented consumption patterns rather than steady, long-term adherence, preventing manufacturers from maximizing the commercial potential of the diagnosed patient population and limiting sustained revenue growth.

The direct impact of these physical health burdens is quantifiable and severe, reducing the overall longevity and stability of the addressable market. According to the World Health Organization in 2025, individuals with schizophrenia had a life expectancy approximately nine years shorter than the general population, a disparity largely attributed to co-occurring physical illnesses such as cardiovascular and metabolic diseases. This elevated mortality rate, often exacerbated by the metabolic side effects of pharmacological interventions, restricts the growth of the patient pool and creates a challenging environment for expanding market penetration.

Market Trends

The integration of digital therapeutics for adherence monitoring and symptom management represents a transformative trend in the Global Schizophrenia Drugs Market, offering a non-pharmacological modality to address unmet needs such as negative symptoms. Unlike traditional pharmacotherapy, these software-based interventions deliver evidence-based therapeutic techniques directly to patients to improve cognitive functioning and motivation while tracking medication compliance in real-time. This approach is gaining significant traction as manufacturers seek to augment drug efficacy with digital tools that can modify disease progression. As reported by Boehringer Ingelheim in October 2025, their investigational prescription digital therapeutic CT-155 demonstrated a statistically significant 6.8-point improvement in negative symptom severity on the CAINS-MAP scale, highlighting the clinical viability of combining digital innovations with standard antipsychotic regimens.

Simultaneously, the expansion of transdermal drug delivery systems is diversifying treatment options beyond oral tablets and long-acting injectables, specifically targeting improved bioavailability and reduced side effects. Transdermal patches provide continuous, controlled release of antipsychotic medication, which can mitigate the peak-trough plasma fluctuations often responsible for adverse events in oral dosing. This delivery method also offers a visual confirmation of adherence for caregivers, addressing a critical challenge in schizophrenia management without the invasiveness of injections. According to Alto Neuroscience's March 2025 financial results, their novel transdermal formulation of ALTO-101 exhibited greater systemic drug exposure than the orally administered version while significantly reducing typical class-related adverse events, underscoring the potential of patch-based technologies to enhance therapeutic indices.

Key Market Players

  • Alkermes Plc
  • Eli Lilly and Company.
  • Johnson & Johnson.
  • AstraZeneca.
  • Pfizer Inc.
  • AbbVie Inc.
  • Otsuka Pharmaceutical Inc.
  • Bristol-Myers Squibb Company.
  • Sumitomo Dainippon Pharma.
  • Acadia Pharmaceuticals.

Report Scope

In this report, the Global Schizophrenia Drugs Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Schizophrenia Drugs Market, By Drug Class

  • First Generation Drugs
  • Second Generation Drugs
  • Third Generation Drugs

Schizophrenia Drugs Market, By Route Of Administration

  • Injectable
  • Oral

Schizophrenia Drugs Market, By Region

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Schizophrenia Drugs Market.

Available Customizations:

Global Schizophrenia Drugs Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Schizophrenia Drugs Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Class (First Generation Drugs, Second Generation Drugs, Third Generation Drugs)
    • 5.2.2. By Route Of Administration (Injectable, Oral)
    • 5.2.3. By Region
    • 5.2.4. By Company (2025)
  • 5.3. Market Map

6. North America Schizophrenia Drugs Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Class
    • 6.2.2. By Route Of Administration
    • 6.2.3. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Schizophrenia Drugs Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Class
        • 6.3.1.2.2. By Route Of Administration
    • 6.3.2. Canada Schizophrenia Drugs Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Class
        • 6.3.2.2.2. By Route Of Administration
    • 6.3.3. Mexico Schizophrenia Drugs Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Class
        • 6.3.3.2.2. By Route Of Administration

7. Europe Schizophrenia Drugs Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Class
    • 7.2.2. By Route Of Administration
    • 7.2.3. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Schizophrenia Drugs Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Class
        • 7.3.1.2.2. By Route Of Administration
    • 7.3.2. France Schizophrenia Drugs Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Class
        • 7.3.2.2.2. By Route Of Administration
    • 7.3.3. United Kingdom Schizophrenia Drugs Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Class
        • 7.3.3.2.2. By Route Of Administration
    • 7.3.4. Italy Schizophrenia Drugs Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Drug Class
        • 7.3.4.2.2. By Route Of Administration
    • 7.3.5. Spain Schizophrenia Drugs Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Drug Class
        • 7.3.5.2.2. By Route Of Administration

8. Asia Pacific Schizophrenia Drugs Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Class
    • 8.2.2. By Route Of Administration
    • 8.2.3. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Schizophrenia Drugs Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Class
        • 8.3.1.2.2. By Route Of Administration
    • 8.3.2. India Schizophrenia Drugs Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Class
        • 8.3.2.2.2. By Route Of Administration
    • 8.3.3. Japan Schizophrenia Drugs Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Class
        • 8.3.3.2.2. By Route Of Administration
    • 8.3.4. South Korea Schizophrenia Drugs Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Drug Class
        • 8.3.4.2.2. By Route Of Administration
    • 8.3.5. Australia Schizophrenia Drugs Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Drug Class
        • 8.3.5.2.2. By Route Of Administration

9. Middle East & Africa Schizophrenia Drugs Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Class
    • 9.2.2. By Route Of Administration
    • 9.2.3. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Schizophrenia Drugs Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Class
        • 9.3.1.2.2. By Route Of Administration
    • 9.3.2. UAE Schizophrenia Drugs Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Class
        • 9.3.2.2.2. By Route Of Administration
    • 9.3.3. South Africa Schizophrenia Drugs Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Class
        • 9.3.3.2.2. By Route Of Administration

10. South America Schizophrenia Drugs Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Drug Class
    • 10.2.2. By Route Of Administration
    • 10.2.3. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Schizophrenia Drugs Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Drug Class
        • 10.3.1.2.2. By Route Of Administration
    • 10.3.2. Colombia Schizophrenia Drugs Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Drug Class
        • 10.3.2.2.2. By Route Of Administration
    • 10.3.3. Argentina Schizophrenia Drugs Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Drug Class
        • 10.3.3.2.2. By Route Of Administration

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Schizophrenia Drugs Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. Alkermes Plc
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Eli Lilly and Company.
  • 15.3. Johnson & Johnson.
  • 15.4. AstraZeneca.
  • 15.5. Pfizer Inc.
  • 15.6. AbbVie Inc.
  • 15.7. Otsuka Pharmaceutical Inc.
  • 15.8. Bristol-Myers Squibb Company.
  • 15.9. Sumitomo Dainippon Pharma.
  • 15.10. Acadia Pharmaceuticals.

16. Strategic Recommendations

17. About Us & Disclaimer